Biocryst Pharmaceuticals (BCRX) Gross Profit (2010 - 2026)

Biocryst Pharmaceuticals' Gross Profit history runs 16 years deep, the most recent figure standing at $151.0 million for Q1 2026.

• Quarterly Gross Profit rose 7.14% year-over-year to $151.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $460.0 million (down 5.72% YoY) and the FY2025 annual result came in at $855.8 million, up 95.18% from the prior year.
• Gross Profit was $151.0 million for Q1 2026 at Biocryst Pharmaceuticals, up from -$8.8 million in the prior quarter.
• Across five years, Gross Profit topped out at $160.6 million in Q2 2025 and bottomed at -$8.8 million in Q4 2025.
• A 5-year average of $95.9 million and a median of $91.5 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit soared 278.25% — and 2025, when it plunged 107.03%.
• Biocryst Pharmaceuticals' Gross Profit stood at $77.2 million in 2022, then gained by 19.03% to $91.8 million in 2023, then soared by 36.58% to $125.4 million in 2024, then slumped by 107.03% to -$8.8 million in 2025, then surged by 1813.59% to $151.0 million in 2026.
• Business Quant data shows BCRX's Gross Profit at $151.0 million in Q1 2026, -$8.8 million in Q4 2025, and $157.2 million in Q3 2025.